-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Fixing the Target on Aggressive Lymphoma: Insights on the Next Phase of Integrating Targeted Agents into MCL and DLBCL Management

Sponsor: AstraZeneca and Lilly
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Lymphomas, Non-Biological therapies, Clinical Research, Combination therapy, genomics, Diseases, aggressive lymphoma, real-world evidence, Therapies, therapy sequence, Lymphoid Malignancies, Biological Processes, Technology and Procedures, profiling, Study Population
Friday, December 9, 2022: 7:00 AM-10:00 AM
Empire CD (Hyatt Regency New Orleans)
Chair:
Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center
Disclosures:
Eyre: Beigene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Secura Bio: Membership on an entity's Board of Directors or advisory committees; Loxo Oncology @ Lilly: Membership on an entity's Board of Directors or advisory committees, Other, Speakers Bureau; PeerView: Speakers Bureau; Medscape: Speakers Bureau.
Speakers:
Jia Ruan, MD, PhD, NewYork-Presbyterian Hospital and Paolo Strati, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Ruan: Pharmacyclics: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Genentech: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Kite Pharma: Consultancy; Celgene: Consultancy, Research Funding; Seattle Genetics: Consultancy; AstraZeneca: Research Funding. Strati: ADC Therapeutics: Consultancy, Research Funding; TG Therapeutics: Consultancy; Kite Gilead: Consultancy; Astrazeneca Acerta: Research Funding; Hutchinson MediPharma: Consultancy; Sobi: Research Funding; ALX Oncology: Research Funding; Roche Genentech: Consultancy.
On Demand program will be available here 2-3 weeks after the ASH meeting.

This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca and Lilly.

Across B-cell non-Hodgkin lymphoma (NHL) settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell) features.

PeerView’s latest “Clinical Consults” event will explore the implications of these new developments by pairing real-world case discussions with mini lecture segments focusing on the present and future of targeted agent classes in aggressive lymphoma settings. Throughout, the experts will highlight evidence supporting novel BTK-based combinations, BTK inhibitor regimens in diverse DLBCL patient populations, and the important safety considerations necessary for successful use of targeted agents in MCL and DLBCL. Register today to learn how to effectively target treatment for your patients with aggressive lymphoma!

Margaret Walker, Peerview Institute For Medical Education
Email: margaret.walker@peerview.com